Categories

XIII Regional Meeting of the Health Technology Assessment Network of the Americas

Washington DC, 22 November 2022 (PAHO)- From 7-9 November 2022 , the XIII Regional Meeting of the Health Technology Assessment Network of the Americas (RedETSA) was held in the city of Brasilia, Brazil. Representatives from 18 countries discussed the Health Technology Assessment (HTA) process at all stages of the technologies’ life cycle, in order to face the challenges of their incorporation into health systems. The event was organized in conjunction with the III Congress of the Brazilian Health Technology Assessment Network – Rebrats.

Marcelo Queiroga, Minister of Health of Brazil; Socorro Gross Galiano, Representative of the PAHO/WHO Country Office in Brazil; Sandra Barros,  Secretary of Science, Technology, Innovation and Strategic Inputs in Health; Vania Canuto,  Director of the Department of Management and Incorporation of Health Technologies; and Alexandre Lemgruber, PAHO Regional Advisor on Health Technologies Management attended the opening of the event.

During the XIII Regional Meeting, open scientific conferences were held and organized according to the different stages of health technologies’ life cycle (regulation-evaluation-incorporation-use-monitoring). A total of 311 people participated in person and 228 virtually thanks to the direct transmission of the event. For more information go to https://www.paho.org/en/news/22-11-2022-xiii-regional-meeting-health-technology-assessment-network-americas

 
Categories

PAHO makes COVID-19 therapeutic available to 16 countries

Washington, DC, 21 December (PAHO) – In an effort to increase equitable access to COVID-19 therapeutics, the Pan American Health Organization (PAHO) delivered more than 11,000 vials of a medication to improve treatment for severe and critically ill COVID-19 patients in 15 Latin American and Caribbean countries.  

Countries that have received the PAHO donation of tocilizumab since mid-September are Belize, Bolivia, Dominica, Dominican Republic, El Salvador, Grenada, Guyana, Haiti, Jamaica, Nicaragua, Peru, St. Lucia, St. Vincent and the Grenadines, Suriname and Venezuela. Panama expects to receive it soon. 

The drug, tocilizumab, has been shown to reduce deaths in hospitalized patients with severe or critical COVID-19, who are rapidly deteriorating or need increased levels of oxygen, and who have a significant inflammatory response.   

The purchase, worth over US$2 million, was procured by PAHO and supported by the Government of the United States. 

For more information go to https://www.paho.org/en/news/21-12-2022-paho-makes-covid-19-therapeutic-available-16-countries

 
Categories

WHO urges action to protect children from contaminated medicines CRM:0557163

Geneva, 23 January 2023 – WHO is releasing an urgent call to action to countries to prevent, detect and respond to incidents of substandard and falsified medical products.
Over the past four months, countries have reported on several incidents of over-the-counter cough syrups for children with confirmed or suspected contamination with high levels of diethylene glycol (DEG) and ethylene glycol (EG). The cases are from at least seven countries, associated with more than 300 fatalities in three of these countries. Most are young children under the age of five. These contaminants are toxic chemicals used as industrial solvents and antifreeze agents that can be fatal even taken in small amounts, and should never be found in medicines.
Based on country reports, WHO has issued three global medical alerts addressing these incidents. The  Medical Product Alert N°6/2022 on 5 October 2022 focused on the outbreak in the Gambia, Medical Product Alert N°7/2022 on 6 November 2022 focused on Indonesia, and Medical Product Alert No1/2023 on 11 January 2023 focused on Uzbekistan.
WHO’s medical product alerts were rapidly disseminated to the national health authorities of all 194 WHO Member States.  These medical product alerts requested, inter alia: (a) the detection and removal of contaminated medicines from circulation in the markets, (b) increased surveillance and diligence within the supply chains of countries and regions likely to be affected, (c) immediate notification to WHO if these substandard products are discovered in-country; and otherwise inform the public of the dangers and toxic effects of the substandard medicines at issue.
Since these are not isolated incidents WHO calls on various key stakeholders engaged in the medical supply chain to take immediate and coordinated action.

For more information go to WHO urges action to protect children from contaminated medicines

 
Categories

Biosimilar and interchangeable biosimilar products – USFDA Curriculum Materials for Health Care Degree Programs

FDA’s curriculum materials are intended to help educate students in health care professional degree programs, for medicine, nursing, physician assistants, and pharmacy, as well as practicing professionals, to improve understanding of biosimilar and interchangeable biosimilar products and the regulatory approval pathway in the United States. For more information go to https://www.fda.gov/drugs/biosimilars/curriculum-materials-health-care-degree-programs-biosimilars

 
Categories

10th Conference of the Pan American Network for Drug Regulatory Harmonization

The COVID-19 pandemic posed a challenge for health systems that had to take regulatory decisions to ensure timely access to medicines and other health technologies, including vaccines, blood and derivatives, medical devices, reagents and in vitro diagnostics that are quality, safe and effective to the population.

The 10th edition of the Conference of the Pan American Network for the Drug Regulatory Harmonization (PANDRH) provides a virtual space to discuss the contribution of regulatory systems in the response to the pandemic, as well as the lessons learned and post-COVID-19 regulatory challenges with PANDRH members and experts from the Region of the Americas and worldwide.

The Conference will take place entirely online on December 6, from 9:30 to noon, December 8 from 9 to 11am, and December 10, from 9 to 11:30am (Washington, D.C. time) and requires advance registration. Sessions will be held in English, Portuguese and Spanish, with the option of simultaneous translation in these languages, as well as in French.

Please register HERE

The quotas to participate in this Conference are limited, so PANDRH Secretariat will prioritize the registrations of representatives of the national regulatory authorities of the Americas region, representatives of the pharmaceutical industry members of ALIFAR and FIFARMA; of economic integration organizations such as CARICOM, MERCOSUR, NAFTA, ALADI, Andean Community; consumer groups; academics; representatives of regional professional associations; and from other groups interested in harmonization and regulatory convergence initiatives.

Note: quotas will be granted to representatives of pharmaceutical industries not affiliated to ALIFAR or FIFARMA as long as they remain vacant after the registration of those considered priority.

*Further information and agenda of the Conference, please click here

 
Categories

Deadline extension to ​​​​​​​15 October 2021

Call for expression of interest to contribute to the value chain and supply of reagents for the sustainable manufacturing of a COVID-19 and other mRNA vaccines in the Americas [Deadline extension from 17 September to ​​​​​​​15 October 2021]

 

For the successful establishment of mRNA vaccine manufacturing capacity globally, the World Health Organization (WHO) has launched a new initiative to support transfer of technology to produce mRNA vaccines in low- and middle-income countries (LMICs) (1). The initiative will ensure that all WHO regions will be able to produce vaccines as essential preparedness measure against future infectious threats.

Under this initiative, WHO and the Pan American Health Organization (PAHO) are working together to establish mRNA vaccine manufacturing capacities in LAC. Currently, there is a limited number of global manufacturers able to supply all necessary reagents and/or starting materials (2) needed for manufacturing mRNA vaccines. To ensure sustainability and independence of vaccine production in the Region, access to reagents that are critical to the value chain is fundamental. Hence PAHO/WHO is launching a call for expression of interest to manufacturers in the Region of the Americas that wish to become part of a regional consortium that will ensure that mRNA vaccines can be sourced from starting materials and preparations (including seed lots, cell banks and intermediates) to the finished product.

Through this new initiative, PAHO and WHO will facilitate the establishment of a Regional consortium and support of a comprehensive technology transfer.  Ideally, the group of manufacturers that come together for this initiative will include representatives from different geographical areas in the Americas and work towards an integrated regional value chain that will provide sustainability and ease the dependence on imported vaccines from outside the Region.

To support this activity, we are seeking expressions of interest from:

  • Public or private manufactures of medical products (drugs, vaccines or drug substances) , and/or starting materials from the Region of the Americas, which could manufacture and supply one or more of the following:
    • DNAse 1,
    • T7 RNA Polymerase,
    • RNase inhibitor,
    • Guanyl Transferase,
    • Pyrophosphatase,
    • GTP,
    • s-adenosyl methionine, and
    • ribonucleotides.

Entities willing to be considered are invited to provide a brief summary that includes, at a minimum, the reagents and/or starting materials they wish to provide, a summary of their capacity, needs, and their interest in participating in this initiative.

Deadline submission

Deadline extension from 17 September to 15 October 2021

This information must be sent to:

MT@paho.org

 


(1). See Call for expression of interest to: Contribute to the establishment of a COVID-19 mRNA vaccine technology transfer hub (who.int)

(2). In accordance with WHO TRS Sixty-sixth report starting materials are: any substances of a defined quality used in the production of a pharmaceutical product but excluding packaging materials. In the context of biological products manufacturing, examples of starting materials may include cryo-protectants, feeder cells, reagents, growth media, buffers, serum, enzymes, cytokines, growth factors and amino acids.

 

Source: https://www.paho.org/en/news/25-8-2021-call-expression-interest-contribute-value-chain-and-supply-reagents-sustainable